These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 35512332)

  • 1. Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination.
    Kurahashi Y; Furukawa K; Sutandhio S; Tjan LH; Iwata S; Sano S; Tohma Y; Ohkita H; Nakamura S; Nishimura M; Arii J; Kiriu T; Yamamoto M; Nagano T; Nishimura Y; Mori Y
    J Infect Dis; 2022 Oct; 226(8):1391-1395. PubMed ID: 35512332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.
    Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M
    Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
    Muik A; Lui BG; Wallisch AK; Bacher M; Mühl J; Reinholz J; Ozhelvaci O; Beckmann N; Güimil Garcia RC; Poran A; Shpyro S; Finlayson A; Cai H; Yang Q; Swanson KA; Türeci Ö; Şahin U
    Science; 2022 Feb; 375(6581):678-680. PubMed ID: 35040667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.
    Zedan HT; Smatti MK; Al-Sadeq DW; Al Khatib HA; Nicolai E; Pieri M; Bernardini S; Hssain AA; Taleb S; Qotba H; Issa K; Abu Raddad LJ; Althani AA; Nasrallah GK; Yassine HM
    J Med Virol; 2024 Mar; 96(3):e29527. PubMed ID: 38511514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants.
    Chang MR; Ke H; Coherd CD; Wang Y; Mashima K; Kastrunes GM; Huang CY; Marasco WA
    EBioMedicine; 2022 Jun; 80():104025. PubMed ID: 35533497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.
    Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Saxton M; Piantadosi A; Waggoner JJ; Douek DC; Rouphael N; Wrammert J; Suthar MS
    Cell Rep Med; 2022 Feb; 3(2):100529. PubMed ID: 35233550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
    Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
    Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
    Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
    Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.
    Cheng SMS; Mok CKP; Leung YWY; Ng SS; Chan KCK; Ko FW; Chen C; Yiu K; Lam BHS; Lau EHY; Chan KKP; Luk LLH; Li JKC; Tsang LCH; Poon LLM; Hui DSC; Peiris M
    Nat Med; 2022 Mar; 28(3):486-489. PubMed ID: 35051989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19-Convalescent Individuals.
    Luczkowiak J; Labiod N; Rivas G; Rolo M; Lasala F; Lora-Tamayo J; Mancheno-Losa M; Rial-Crestelo D; Pérez-Rivilla A; Folgueira MD; Delgado R
    J Infect Dis; 2022 Jun; 225(11):1905-1908. PubMed ID: 34963008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies.
    Lusvarghi S; Pollett SD; Neerukonda SN; Wang W; Wang R; Vassell R; Epsi NJ; Fries AC; Agan BK; Lindholm DA; Colombo CJ; Mody R; Ewers EC; Lalani T; Ganesan A; Goguet E; Hollis-Perry M; Coggins SA; Simons MP; Katzelnick LC; Wang G; Tribble DR; Bentley L; Eakin AE; Broder CC; Erlandson KJ; Laing ED; Burgess TH; Mitre E; Weiss CD
    Sci Transl Med; 2022 May; 14(645):eabn8543. PubMed ID: 35380448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
    Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
    J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
    Gruell H; Vanshylla K; Tober-Lau P; Hillus D; Schommers P; Lehmann C; Kurth F; Sander LE; Klein F
    Nat Med; 2022 Mar; 28(3):477-480. PubMed ID: 35046572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron variants in maternal and cord blood.
    Govindaraj S; Cheedarla N; Cheedarla S; Irby LS; Neish AS; Roback JD; Smith AK; Velu V
    Front Immunol; 2023; 14():1211558. PubMed ID: 37465682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.
    Serrano-Conde E; Leyva A; Fuentes A; de Salazar A; Chueca N; Pérez-Castro S; Regueiro B; Rojas A; Mendoza J; Rojas J; García F
    Transbound Emerg Dis; 2022 Sep; 69(5):2649-2655. PubMed ID: 34910373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Neutralization After Antenatal Messenger RNA Vaccination.
    Rottenstreich A; Vorontsov O; Alfi O; Zarbiv G; Oiknine-Djian E; Zigron R; Kleinstern G; Mandelboim M; Porat S; Wolf DG
    Clin Infect Dis; 2022 Nov; 75(11):2023-2026. PubMed ID: 35607735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.